ASTRAZENECA PLC
AZNNYSE
$168.90
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +21.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
AstraZeneca PLC focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. The company serves primary care and specialty care physicians through distributors in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
- CEO
- Pascal Soriot
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 83,500
- Website
- astrazeneca.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jul 20, 2026
Jul 18, 2026
Jul 17, 2026
Jul 16, 2026
- 4d agoMerck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pillfinance.yahoo.com
- 4d agoSLN Stock Skyrockets 107% in Six Months: Here's What You Need to Knowfinance.yahoo.com
- 4d agoAttractive Growth Profile Positions AstraZeneca PLC (AZN) as Opportunityfinance.yahoo.com
- 4d agoMerck Gets Approval for Powerful Cholesterol-Cutting Pillfinance.yahoo.com
Jul 15, 2026
- 5d agoAZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drugfinance.yahoo.com
- 5d agoAstraZeneca (LSE:AZN) Secures Zegfrovy In $1.5 Billion Lung Cancer Licensing Dealfinance.yahoo.com
- 5d agoKairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Marketfinance.yahoo.com
- 5d agoEli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Millionfinance.yahoo.com
- 5d agoJ&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsbiopharmadive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Sharma Mani· See Remarks | Award | 2 | $190.43 | $380.86 | filing |
| 2026-06-08 | Sharma Mani· See Remarks | Award | 1 | $179.75 | $179.75 | filing |
| 2026-05-20 | Sharma Mani· See Remarks | Sale | 11,893 | $185.78 | $2.2M | filing |
| 2026-05-06 | Sharma Mani· See Remarks | Award | 1 | $186.28 | $186.28 | filing |
| 2026-04-07 | Sharma Mani· See Remarks | Award | 1 | $196.03 | $196.03 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.